Beyond chronic pain: How best to treat psychological comorbidities

,; ,; ,; ,; ,; ,; ,

Applied Evidence

Beyond chronic pain: How best to treat psychological comorbidities

J Fam Pract. 2014 May;63(5):260-264

PDF Download

References

1. Boulanger A, Clark AJ, Squire P, et al. Chronic pain in Canada: have we improved our management of chronic noncancer pain? Pain Res Manag. 2007;12:39-47.

2. Attal N, Lanteri-Minet M, Laurent B, et al. The specific disease burden of neuropathic pain: results of a French nationwide survey. Pain. 2011;152:2836-2843.

3. Bigatti SM, Hernandez AM, Cronan TA, et al. Sleep disturbances in fibromyalgia syndrome: relationship to pain and depression. Arthritis Rheum. 2008;59:961-967.

4. Morin CM, Gibson D, Wade J. Self-reported sleep and mood disturbance in chronic pain patients. Clin J Pain. 1998;14:311-314.

5. Onen SH, Alloui A, Gross A, et al. The effects of total sleep deprivation, selective sleep interruption and sleep recovery on pain tolerance thresholds in healthy subjects. J Sleep Res. 2001;10:35-42.

6. Naughton F, Ashworth P, Skevington SM. Does sleep quality predict pain-related disability in chronic pain patients? The mediating roles of depression and pain severity. Pain. 2007;127:243-252.

7. Bair MJ, Robinson RL, Katon W, et al. Depression and pain comorbidity: a literature review. Arch Intern Med. 2003;163:2433-2445.

8. Gureje O, Simon GE, Von Korff M. A cross-national study of the course of persistent pain in primary care. Pain. 2001;92:195-200.

9. McWilliams LA, Goodwin RD, Cox BJ. Depression and anxiety associated with three pain conditions: results from a nationally representative sample. Pain. 2004;111:77-83.

10. Jordan KD, Okifuji A. Anxiety disorders: differential diagnosis and their relationship to chronic pain. J Pain Palliat Care Pharmacother. 2011;25:231-245.

11. El-Gabalawy R, Mackenzie CS, Shooshtari S, et al. Comorbid physical health conditions and anxiety disorders: a population-based exploration of prevalence and health outcomes among older adults. Gen Hosp Psychiatry. 2011;33:556-564.

12. International Narcotics Control Board Web site. Report of the International Narcotics Control Board for 2012. Available at: http://www.incb.org/documents/Publications/AnnualReports/AR2012/AR_2012_E.pdf. Published January 2013. Accessed November 9, 2013.

13. Currie CL, Schopflocher DP, Wild TC. Prevalence and correlates of 12-month prescription drug misuse in Alberta. Can J Psychiatry. 2011;56:27-34.

14. Trust for America’s Health Web site. Prescription drug abuse: Strategies to stop the epidemic 2013. Available at: http://healthyamericans.org/assets/files/TFAH2013RxDrugAbuseRptFINAL.pdf. Published October 2013. Accessed November 14, 2013.

15. Olsen Y, Alford DP. Chronic pain management in patients with substance use disorders. Johns Hopkins Adv Stud Med. 2006;6:111-123.

16. Alford DP. Opioids for chronic pain in patients with substance abuse: too much, too little or just right? Pain. 2009;145:267-268.

17. Krashin D, Murinova N, Ballantyne J. Management of pain with comorbid substance abuse. Curr Psychiatry Rep. 2012;14:462-468.

18. Gelenberg AJ, Freeman MP, Markowitz JC, et al. Practice guideline for the treatment of patients with major depressive disorder. Third Edition. Available at: http://psychiatryonline.org/pdfaccess.ashx?ResourceID=243261&PDFSource=6. Published October 2010. Accessed April 22, 2014.

19. McQuay HJ, Moore RA. Antidepressants and chronic pain. BMJ. 1997;314:763-764.

20. Dworkin RH, Corbin AE, Young JP Jr, et al. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebocontrolled trial. Neurology. 2003;60:1274-1283.

21. Serpell MG; Neuropathic pain study group. Gabapentin in neuropathic pain syndromes: a randomised, double-blind, placebo-controlled trial. Pain. 2002;99:557-566.

22. Richter RW, Portenoy R, Sharma U, et al. Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J Pain. 2005;6:253-260.

23. Feltner D, Wittchen HU, Kavoussi R, et al. Long-term efficacy of pregabalin in generalized anxiety disorder. Int Clin Psychopharmacol. 2008;23:18-28.

24. Bollu V, Bushmakin AG, Cappelleri JC, et al. Pregabalin reduces sleep disturbance in patients with generalized anxiety disorder via both direct and indirect mechanisms. Eur J Psychiat. 2010;24:18-27.

25. Moore RA, Wiffen PJ, Derry S, et al. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2011;(3):CD007938.

26. Chandramouli, J. Newer anticonvulsant drugs in neuropathic pain and bipolar disorder. J Pain Palliat Care Pharmacother. 2002;16:19-37.

27. Moulin DE, Clark AJ, Gilron I, et al; Canadian Pain Society. Pharmacological management of chronic neuropathic pain: consensus statement and guidelines from the Canadian Pain Society. J Pain Res Manag. 2007;12:13-21.

28. Whyte IM, Dawson AH, Buckley NA. Relative toxicity of venlafaxine and selective serotonin reuptake inhibitors in overdose compared to tricyclic antidepressants. QJM. 2003;96:369-374.

29. Bosch TM, van der Werf TS, Uges DR, et al. Antidepressants selfpoisoning and ICU admissions in a university hospital in The Netherlands. Pharm World Sci. 2000;22:92-95.

30. Arnold LM, Palmer RH, Gendreau RM, et al. Relationships among pain, depressed mood, and global status in fibromyalgia patients: post hoc analyses of randomized, placebo-controlled trial of milnacipran. Psychosomatics. 2012;53:371-379.

31. Marangell LB, Clauw DJ, Choy E, et al. Comparative pain and mood effects in patients with comorbid fibromyalgia and major depressive disorder: secondary analyses of four pooled randomized controlled trials of duloxetine. Pain. 2011;152:31-37.

32. Begré S, Traber M, Gerber M, et al. Change in pain severity with open label venlafaxine use in patients with a depressive symptomatology: an observational study in primary care. Eur Psychiatry. 2008;23:178-186.

33. Branco JC, Zachrisson O, Perrot S, et al; Multinational Coordinator Study Group. A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial of milnacipran in the treatment of fibromyalgia. J Rheumatol. 2010;37:851-859.

34. Salín-Pascual RJ, Galicia-Polo L, Drucker-Colin R. Sleep changes after 4 consecutive days of venlafaxine administration in normal volunteers. J Clin Psychiatry. 1997;58:348-350.

35. Otto M, Bach FW, Jensen TS, et al. Escitalopram in painful polyneuropathy: a randomized, placebo-controlled, cross-over trial. Pain. 2008;139:275-283.

36. Max MB, Lynch SA, Muir J, et al. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med. 1992;326:1250-1256.

37. Sellek S. Opioid abuse puts physicians between a rock and a hard place but resources can help them lead the debate on how to rein it in. Mich Med. 2013;112:10-13.

38. Nielsen S, Bruno R, Degenhardt L, et al. The sources of pharmaceuticals for problematic users of benzodiazepines and prescription opioids. Med J Aust. 2013;199:696-699.

39. Turk DC, Swanson KS, Tunks ER. Psychological approaches in the treatment of chronic pain patients–when pills, scalpels, and needles are not enough. Can J Psychiatry. 2008;53:213-223.

40. Basler HD, Jäkle C, Kröner-Herwig B. Incorporation of cognitive-behavioral treatment into the medical care of chronic low back patients: a controlled randomized study in German pain treatment centers. Patient Educ Couns. 1997;31:113-124.

41. Middaugh S, Thomas KJ, Smith AR, et al. EMG biofeedback and exercise for treatment of cervical and shoulder pain in individuals with a spinal cord injury: a pilot study. Top Spinal Cord Inj Rehabil. 2013;19:311-323.

42. Oravitan M, Avram C. The effectiveness of electromyographic biofeedback as part of a meniscal repair rehabilitation programme. J Sports Sci Med. 2013;12:526-532.eCollection 2013.

43. Glombiewski JA, Bernardy K, Häuser W. Efficacy of EMG- and EEG-biofeedback in fibromyalgia syndrome: A meta-analysis and a systematic review of randomized controlled trials. Evid Based Complement Alternat Med. 2013;2013:962741.

44. Kubik A, Biedroń A. Neurofeedback therapy in patients with acute and chronic pain syndromes—literature review and own experience. Przegl Lek. 2013;70:440-442.

45. Overcash J, Will KM, Lipetz DW. The benefits of medical qigong in patients with cancer: a descriptive pilot study. Clin J Oncol Nurs. 2013;17:654-658.

46. Jastrowski Mano KE, Salamon KS, Hainsworth KR, et al. A randomized, controlled pilot study of mindfulness-based stress reduction for pediatric chronic pain. Altern Ther Health Med. 2013;19:8-14.

47. Ahmed M, Modak S, Sequeira S. Acute pain relief after Mantram meditation in children with neuroblastoma undergoing anti-GD2 monoclonal antibody therapy. J Pediatr Hematol Oncol. 2014;36:152-155.

48. Romano JM, Turner JA. Chronic pain and depression: does the evidence support a relationship? Psychol Bull. 1985;97:18-34.

The opioids tramadol and methadone are recommended as third-line therapy, along with nonopioid medications such as cannabinoids, lamotrigine, topiramate, and valproic acid.²⁷

Use a comprehensive pain scale, such as the Brief Pain Inventory, to assess the pain of any patient with a history of a substance-related disorder rather than asking him or her to rate the pain level on a general Likert-type scale.¹⁵

Long-acting opioids, such as sustained-release morphine, oxycodone, or fentanyl patch, are preferable to short-acting immediate-release opioids, which have a higher addictive profile because of their fast onset of action.¹⁵ Keep in mind, however, that long-acting opioids also have the potential for abuse, and patients taking them must be carefully monitored, as well.

Nonpharmacologic therapy often helps, too

Instead of using a Likert-type scale, use a comprehensive pain scale, such as the Brief Pain Inventory, to assess pain in patients with a history of a substance-related disorder.Evidence suggests that even the most potent drugs significantly decrease pain in only about half of those taking them.³⁹ And whether or not adequate pain relief is achieved, patients with the constellation of pain and sleep, mood, anxiety, and/or substance disorders can benefit from nonpharmacologic interventions, as well. Let patients know that CBT, in particular, has been shown to have a positive effect on psychological function and comorbid psychological disorders, particularly when it is combined with pharmacologic therapy.⁴⁰ In addition, other nonpharmacologic treatments, including biofeedback^41-44 and meditation,^45-47 have shown preliminary value in managing pain.

Further research is needed to understand the effectiveness of CBT in the management of chronic pain; however, it appears that CBT may have a positive effect on psychological functioning and comorbid psychological disorders.

The bottom line: Don’t overlook mood, anxiety symptoms in pain patients

In epidemiological studies of chronic pain, it is apparent that sleep, depressive, substance abuse/dependence, and anxiety syndromes often occur together, which supports the necessity of considering psychosocial dynamics to understand pain. Although there has been some inconsistency observed across findings (eg, Romano and Turner),⁴⁸ clarifying the relationships amongst these disorders may be an avenue for future research. The literature to date suggests that mood- and anxiety-related symptoms should not be overlooked in pain patients, as there is a negative effect on prognosis when these disorders co-occur.⁶

CBT has a positive effect on psychological comorbidities, especially when combined with medication. Treatment should be based on individual patient factors, such as presenting symptoms and potential for drug side effects. Some pharmacologic agents have been shown to be effective in treating several symptoms of this pyramid. Such drugs offer the best success and relapse rates, and reduce the likelihood of drug interactions. CBT appears to offer added benefits, especially if combined with pharmacology. However, few controlled trials have been conducted in this area and further research is required to appropriately guide clinical management.

CORRESPONDENCE
Martin A. Katzman, MD, FRCPC, START Clinic for Mood and Anxiety Disorders, 32 Park Road, Toronto, Ontario, Canada M4W 2N4; mkatzman@startclinic.ca